In line with ibrutinib, the first generation BTK inhibitor, which blocks plasmablast generation and production of autoantibodies in systemic lupus erythematosus [54–56], zanubrutinib reduced AQP4–IgG production in vitro. Here, BTK is linked to systemic lupus erythematosus.